Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L)
- Target
- MTHFD1L
- Molecular classification
- Enzyme, Folate cycle enzyme, Mitochondrial monofunctional enzyme
01
Overview
Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) is a mitochondrial monofunctional enzyme possessing formyl-tetrahydrofolate synthetase activity critical to the folate cycle and one-carbon metabolism. It generates formate in mitochondria, enabling nucleotide and methionine biosynthesis, and is implicated in the growth and progression of multiple cancers through its role in cellular metabolism. Overexpression of MTHFD1L is associated with poor prognosis in several tumor types and affects immune cell infiltration in the microenvironment. Drug modulation of this enzyme can impact cancer cell survival and metabolic activity, making it an emerging focus for therapeutic intervention.
- Other names
- MTHFD1LMethylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-likemitochondrial C1-THF synthase
02
Mechanism of action
Inhibition or modulation of MTHFD1L can reduce cancer cell proliferation and invasive potential; targeting impairs nucleotide and formate biosynthesis necessary for tumor growth.
03
Biological functions
One-carbon metabolismFormate synthesisMaintenance of folate cycleRegulation of nucleotide biosynthesisCell proliferation
04
Disease associations
Cancer (including colorectal cancer, bladder cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer)Metabolic disorders
05
Safety considerations
Potential for off-target effects on mitochondrial function and nucleotide synthesisPossible impact on normal one-carbon metabolism and folate-associated pathways, leading to immune or hematological disturbances
06
Interacting drugs
Cisplatin (upregulates expression)
4 more in the full profile.
07
Biomarkers
MTHFD1L overexpression (diagnostic/prognostic in various cancers: bladder, head and neck, kidney, lung, uterine)Correlation with poor patient survival in several cancer subtypes
Beyond the preview
Go deeper on Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L).